Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s exactly what’s at stake. Big fat insurance policy.
Nice recovery — 2.40!
Agree Grip. It’s challenging and unnerving to watch NP deliver the news. Respect his work ethic and passion. He understands Leronlimab better than anyone - unfortunately his communication skills are not his forte.
Great synopsis. LMAO with your closing sentence.
Nothing to be stumped about HH. This is the way it rolls. Sell off to be expected after a run up from .30 to $3 plus. Next round of data will play in Leronlimab’s favor. The tipping point is coming. We are little CYDY on the OTC not Gilead or Sanofi.
We have to validate our anecdotal evidence to change the big picture. That’s the process we are navigating quite nicely right now.
Around the clock.
It’s only a matter of time until the data stacks to the tipping point. Drug works — Period.
When the SP meets requirements, The cash will appear. Mark my words.
Nice way of stating things Zuess.
They scare because they are new SH’s. Many bought into CYDY in the last couple of weeks. We also have profit taking from those that converted warrants. Retracting to the low $2’s is to be expected IMO without daily positive news.
The core pre Covid-19 Longs are averaged in below $1. We get the science and are thrilled to be in the position we are in because we know what is in front of us.
There are three major near term catalysts that are going to move the SP substantially above $3 and I believe they will happen in this order.
—HIV Combo BLA submission
—Covid-19 FDA approval
—Uplist to the Nasdaq
The big valuation increase is coming after we move through the Civid-19 play and onto our core focus - HIV and Cancer.
Misiu, you know better than all of us the science will not be stopped.
Scared sheep is right. People get emotional and forget about why they invested. The Covid -19 story is further along and more viable for Leronlimab that it was last week.
It will be approved because it works. The meat which is HIV and Cancer is the home run, Covid-19 is the icing on the cake - be patient the cake hasn’t come out of the oven yet.
We need to fill this 75 patient trial ASAP. We know and the overseeing Docs know the results are and will be stellar.
Thanks BL. It’s been a long road and we have come far. It’s a tough game as my long time money manager told me - one earns every penny with an investment like this.
I have quite a number of high IQ investors that have jumped in in the last week because it’s such an intriguing play. The drug works on many indications and Covid-19 is the gateway to mainstream recognition.
Good luck to you and all the other Longs.
As I recapped the posts today and watched the news I sensed a couple of movements.
First of all the nervousness of those shorting CYDY is warranted.
Listening to the national evening news I could feel the gasp of relief when Leronlimab wasn’t mentioned. The BP drugs took the spotlight with little hope as a treatment.
It doesn’t take a high level of intelligence if one is following Leronlimab to see what is going to happen in the coming days or at the outside possibly weeks — LENRONLIMAB is going to be headline news.
The results are stacking. The 75 patient positive clinical trial data is going to spread and the EIND results will continue to multiply. It’s not a question of approval it’s a question of when will the FDA cave.
Just to nip it in the bud, let me be clear. Leronlimab is not a vaccine, it’s not a cure, it’s a treatment for those that contract the deadly Covid-19.
Secondly I could feel the impatience from the Investors that support and understand the science behind this multifaceted molecule. We want recognition and confirmation now - this a political sham, a power play that is wrong.
Remain patient yet vigilant at the same time. The tipping point is near and we have a bulldog at the helm. We will not be denied.
Never have I been more confident in an outcome in my life. The world needs this and they will have it.
I think this response to the Remdesivir critique sums it up.
“While many articles such as this discuss the flaws in big pharma’s attempts at a treatment, a small biotech, CytoDyn, has an investigational drug, leronlimab, that is showing fantastic efficacy. This drug is now in FDA Phase 2 trails for mild to moderate infections and Phase 2b/3 for serious illness. It appears to be batting 1000 against the cytokine storm and is restoring patient’s immune response to fight the infection. Several patients have been discharged within only a few days of treatment”
Absolutely. These guys are barking up the wrong tree. Actually that are barking up the most threatening tree.
Yes we will.
No, your way over the top. Let’s take a vote. You’ll get one from Eddy and that’s all.
Powerful Bobby. Brought a tear to my eye.
Keen observation. What we don’t know is how many of those warrants that were converted to shares were converted with the intention to sell immediately.
Many are held by investors that don’t take chances and the only reason they convert is to immediately sell, bank the profit and move on.
There is another smaller group that converts with the intention to hold and sell when the SP appreciates further.
I converted all of my warrants through the Tender Offer because it was well worth the risk. The SP was around .40 at the time and the net result was a cost of .266 per share converted. Many Longs took advantage of this offering in June of 2019 for the purpose of holding.
I found this process most interesting when I moved all of my shares from RBC (Paulson’s holding bank for the private raises) to Fidelity. Fidelity was the only brokerage that would take the shares. Moving the shares was most challenging because the normal ACAT electronic transfer was not an option with RBC.
Here’s the punch line — I dealt with a true professional with decades of experience at Fidelity who runs the Restricted Shares Dept. I asked him how often he sees warrants exercised on the OTC? He said basically never — it’s like the total eclipse of the sun —it just doesn’t happen. That translates to almost all of these deals end up BK or languish in the OTC gutter.
The fact that CYDY is in its current position with millions of warrants being exercised supported by a molecule that works in so many indications is like finding a needle in a haystack. That’s why the naysayers and shorts just can’t buy into Leronlimab being the real deal. They bet on the odds.
They’d be wise to repopulate their fact sheet and recalculate the current probability of success here. Much has changed in the last year and that’s an understatement.
Onward and upward!
No he doesn’t — it’s a habit. And as they say habits are hard to break.
Your reaching at a level that is now become your own story. Pure fabrication - how desperate are you?
That is certainly the best option. First things first. Corona FDA emergency approval first. That will be the game changer. What an ironic event ironic event that would be for this CYDY.
$10 SP for Corona. That’s $7B.
A little further down the road with the Cancer indications and HIV Mono and the price goes way up.
A buy out offer in that range would be interesting for SH’s to consider. I’m sure there are many that would want substantially more and be quite upset if their investment was let go at that valuation. It would be a lucrative problem to have.
I’m not greedy.
Leronlimab is not going to be stopped. The results are just too overwhelmingly positive — and they are going to keep on coming.
You can’t just do that and you know it. That day is coming though once patients agree and are in the right mental state after nearly dying.
You are in a very awkward position pushing your agenda and hoping Leronlimab fails while the rest of the US and world is cheering it on praying for the exact opposite.
And that begs the question who in their right mind would be out of this stock over the weekend?
The way the results are moving more patients injected, more results coming daily, FDA reviewing data, three days is an eternity.
What a great three day weekend coming up. Would be better if we were saving so many more lives RIGHT NOW.
It’s all relative. Especially if you were still holding. That’s the relativity
Market is not open yet and CYDY is the most posted and most read board.
That’s quite an accomplishment with not one post from Just and Eddie to artificially inflate the numbers.
Good news is good news. Many long time investors own big positions.
Being Optimistic about the results coming is not childish - it’s a legitimate game changer.
Nader is not my cup of tea. I have tempered that with my expectations. Having said that I don’t believe the drug can be held back regardless.
Like it or not Covid-19 has and will continue to garner national exposure.
Don’t doubt you’ve made lots of $. You missed this one and your posts tell the story.
So one patient removed from ventilator after three days on Leronlimab after exhausting all other drugs.
Two more patients released from hospital after being injected.
Waiting on the results of four more patients that were injected at same hospital in Souther Cal.
That’s a total of 7 new patients with three excellent results.
This means enrollment will be off to a frenzied pace. We could likely see many more results with the same outcome on a daily basis.
This looks like the inflection point fast approaching. Get Leronlimab approved and start saving lives now.
Thanks Monroe for clearly stating the truth.
It’s all common sense if one does their DD. Your an experienced investor that sees the forest for the trees. Glad to have your clear perspectives to set the story straight.
The reality is CYDY is ahead of the curve. The average to make it to FDA approval is $1B and 10 years. We are on the cusp of our first approval with $200M raised and seven years in. That translates to 80% below the norm for cost and 30% ahead of the time line.
As for revenue it’s simple you can’t commercialize until you have the green light from the FDA. HIV Combo BLA submitted in the next few days and approval imminent Q4 of this year. In addition strong possibility of FDA approval for Covid-19 in the coming weeks not to mention the many other Cancer indications.
Bottom line is investors getting in at $3 have a safety net being invested in a min $5 stock with HIV Combo alone. There’s a lot going on here in the short term that can send this stock North in a hurry.
Keep reaching and spinning. Your imagination is pure science fiction at best.
No just respect.
Onward and upward Misiu. We are making history.
I have to pinch myself when I think about the impact we are going to have on mankind. Thankful and proud to be invested in Cytodyn.
Keep the great posts coming Misiu. Your our expert medical professional that can keep the science in perspective. Many thanks.
On another note these guys are really ugly souls. They distort and rant about anything they can spin at the toon of close to 100 posts a day. It’s just what they do for a living.
I have no respect for them as they really don’t care about the good that will come from this molecule. The good news is they are both little fish trying to find a buck to buy their next meal.
Here we go. Nader’s up next. Biggest moment of his Cytodyn career.
Exactly.
All these new investors will be pleased to discover Covid-19 is the tip of the spear. The meat is HIV, mTNBC, and 20 plus additional cancer indications, with HIV drug approval expected later
this year.
It’s a huge advantage to get into a Covid-19 play with so much promise. A free insurance policy with CYDY’s valuation substantially North of $3 even when Covid-19 is subtracted from the mix.
Leronlimab is going to deliver consistently by saving lives and taking very sick patients off ventilators. What’s that worth? These very sick patients that are on ventilators exhausted the big two options - Hydroxychloroquine and Remdesivir to no avail. If Leronlimab can bring that type of patient back to health what can it do earlier in the progression of Covid-19?
That is one of many questions that will be answered a day at a time. The results and data just continue to stack. The tipping point is approaching. Place your bets.
Do the math. 100k doses x $300 per dose COGS = $30M.
Thats the number you keep ranting about.
Next rant?
Here’s what I heard for sure. 2 out of the first 10 extubated. 2 out of patients 11-15 have been extubated. The remaining 8 out of the first 10 patients are showing steady progress. ALL of of these very sick patients have exhausted the Malari drug and Remdesivir and were on their death bed. Leronlimab is bringing all of them back.
Updates will be coming daily and the truth will be told. More patients, more results, and more patients coming off ventilators.
The tipping point could come on Wednesday on Fox national news. The country wants hope we have more than hope.
IMHO.